A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

J. S. Rader, D. Clarke-Pearson, M. Moore, L. Carson, R. Holloway, M. S. Kao, Israel Wiznitzer, E. C. Douglass

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. This Phase II, multicenter, open-label study was conducted to assess the efficacy and tolerability of ZD9331, a novel direct-acting thymidylate synthase inhibitor, in heavily pretreated patients with ovarian cancer. Methods. The study recruited 44 women with ovarian cancer or primary peritoneal cancer previously treated with platinum therapy and paclitaxel and with progressive disease after, or intolerance to, topotecan administered as the most recent therapy. ZD9331 was administered as an intravenous infusion at 130 mg/m2 on Days 1 and 8 of 3-week cycles, until objective evidence of disease progression. A cutoff date of 3 months after the last patient received the first dose was set for data collection. Results. Patients received a mean of 3.3 cycles of ZD9331 and a total of 143 cycles were administered. Among the 42 patients evaluated for best overall tumor response, one achieved a complete response and two achieved a partial response, giving an objective tumor response rate of 7%. The complete response occurred at Day 15 of Cycle 2 in a patient receiving ZD9331 as her eighth-line therapy. Seven patients had stable disease, giving a disease control rate of 23%. Thirty-one patients (71%) had disease progression and the median time to progression was 53 days. Most patients (89%) experienced drug-related adverse events, most commonly nausea (73%), vomiting (48%), and neutropenia (50%). Six patients (14%) were withdrawn from treatment due to adverse events. Conclusions. The preliminary evidence of efficacy and acceptable tolerability of ZD9331 in this heavily pretreated population with ovarian cancer warrants further investigation, especially in a less heavily pretreated patient population.

Original languageEnglish
Pages (from-to)318-325
Number of pages8
JournalGynecologic Oncology
Volume91
Issue number2
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Disease Progression
ZD 9331
Topotecan
Thymidylate Synthase
Neoplasms
Therapeutics
Paclitaxel
Neutropenia
Platinum
Drug-Related Side Effects and Adverse Reactions
Intravenous Infusions
Nausea
Population
Vomiting

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. / Rader, J. S.; Clarke-Pearson, D.; Moore, M.; Carson, L.; Holloway, R.; Kao, M. S.; Wiznitzer, Israel; Douglass, E. C.

In: Gynecologic Oncology, Vol. 91, No. 2, 01.11.2003, p. 318-325.

Research output: Contribution to journalArticle

Rader, J. S. ; Clarke-Pearson, D. ; Moore, M. ; Carson, L. ; Holloway, R. ; Kao, M. S. ; Wiznitzer, Israel ; Douglass, E. C. / A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. In: Gynecologic Oncology. 2003 ; Vol. 91, No. 2. pp. 318-325.
@article{8495cbeb7aa84d68bca70c5e62566176,
title = "A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer",
abstract = "Background. This Phase II, multicenter, open-label study was conducted to assess the efficacy and tolerability of ZD9331, a novel direct-acting thymidylate synthase inhibitor, in heavily pretreated patients with ovarian cancer. Methods. The study recruited 44 women with ovarian cancer or primary peritoneal cancer previously treated with platinum therapy and paclitaxel and with progressive disease after, or intolerance to, topotecan administered as the most recent therapy. ZD9331 was administered as an intravenous infusion at 130 mg/m2 on Days 1 and 8 of 3-week cycles, until objective evidence of disease progression. A cutoff date of 3 months after the last patient received the first dose was set for data collection. Results. Patients received a mean of 3.3 cycles of ZD9331 and a total of 143 cycles were administered. Among the 42 patients evaluated for best overall tumor response, one achieved a complete response and two achieved a partial response, giving an objective tumor response rate of 7{\%}. The complete response occurred at Day 15 of Cycle 2 in a patient receiving ZD9331 as her eighth-line therapy. Seven patients had stable disease, giving a disease control rate of 23{\%}. Thirty-one patients (71{\%}) had disease progression and the median time to progression was 53 days. Most patients (89{\%}) experienced drug-related adverse events, most commonly nausea (73{\%}), vomiting (48{\%}), and neutropenia (50{\%}). Six patients (14{\%}) were withdrawn from treatment due to adverse events. Conclusions. The preliminary evidence of efficacy and acceptable tolerability of ZD9331 in this heavily pretreated population with ovarian cancer warrants further investigation, especially in a less heavily pretreated patient population.",
author = "Rader, {J. S.} and D. Clarke-Pearson and M. Moore and L. Carson and R. Holloway and Kao, {M. S.} and Israel Wiznitzer and Douglass, {E. C.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1016/S0090-8258(03)00491-8",
language = "English",
volume = "91",
pages = "318--325",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

AU - Rader, J. S.

AU - Clarke-Pearson, D.

AU - Moore, M.

AU - Carson, L.

AU - Holloway, R.

AU - Kao, M. S.

AU - Wiznitzer, Israel

AU - Douglass, E. C.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Background. This Phase II, multicenter, open-label study was conducted to assess the efficacy and tolerability of ZD9331, a novel direct-acting thymidylate synthase inhibitor, in heavily pretreated patients with ovarian cancer. Methods. The study recruited 44 women with ovarian cancer or primary peritoneal cancer previously treated with platinum therapy and paclitaxel and with progressive disease after, or intolerance to, topotecan administered as the most recent therapy. ZD9331 was administered as an intravenous infusion at 130 mg/m2 on Days 1 and 8 of 3-week cycles, until objective evidence of disease progression. A cutoff date of 3 months after the last patient received the first dose was set for data collection. Results. Patients received a mean of 3.3 cycles of ZD9331 and a total of 143 cycles were administered. Among the 42 patients evaluated for best overall tumor response, one achieved a complete response and two achieved a partial response, giving an objective tumor response rate of 7%. The complete response occurred at Day 15 of Cycle 2 in a patient receiving ZD9331 as her eighth-line therapy. Seven patients had stable disease, giving a disease control rate of 23%. Thirty-one patients (71%) had disease progression and the median time to progression was 53 days. Most patients (89%) experienced drug-related adverse events, most commonly nausea (73%), vomiting (48%), and neutropenia (50%). Six patients (14%) were withdrawn from treatment due to adverse events. Conclusions. The preliminary evidence of efficacy and acceptable tolerability of ZD9331 in this heavily pretreated population with ovarian cancer warrants further investigation, especially in a less heavily pretreated patient population.

AB - Background. This Phase II, multicenter, open-label study was conducted to assess the efficacy and tolerability of ZD9331, a novel direct-acting thymidylate synthase inhibitor, in heavily pretreated patients with ovarian cancer. Methods. The study recruited 44 women with ovarian cancer or primary peritoneal cancer previously treated with platinum therapy and paclitaxel and with progressive disease after, or intolerance to, topotecan administered as the most recent therapy. ZD9331 was administered as an intravenous infusion at 130 mg/m2 on Days 1 and 8 of 3-week cycles, until objective evidence of disease progression. A cutoff date of 3 months after the last patient received the first dose was set for data collection. Results. Patients received a mean of 3.3 cycles of ZD9331 and a total of 143 cycles were administered. Among the 42 patients evaluated for best overall tumor response, one achieved a complete response and two achieved a partial response, giving an objective tumor response rate of 7%. The complete response occurred at Day 15 of Cycle 2 in a patient receiving ZD9331 as her eighth-line therapy. Seven patients had stable disease, giving a disease control rate of 23%. Thirty-one patients (71%) had disease progression and the median time to progression was 53 days. Most patients (89%) experienced drug-related adverse events, most commonly nausea (73%), vomiting (48%), and neutropenia (50%). Six patients (14%) were withdrawn from treatment due to adverse events. Conclusions. The preliminary evidence of efficacy and acceptable tolerability of ZD9331 in this heavily pretreated population with ovarian cancer warrants further investigation, especially in a less heavily pretreated patient population.

UR - http://www.scopus.com/inward/record.url?scp=0242352428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242352428&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00491-8

DO - 10.1016/S0090-8258(03)00491-8

M3 - Article

VL - 91

SP - 318

EP - 325

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -